• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

The Weekly Roundup: August 29-September 2

Article

ICYMI, this week we had stories about non-prescription acne treatments, clinical study results, pediatric atopic dermatitis, and the EADV 2022 Congress.

POLL: Which September FDA Approval Are You Looking Forward To?

Click here to answer this week's poll.

Role of Nonprescription Acne Treatments

Expert dermatologists discuss the impact of nonprescription acne treatment on quality of life and function.

Types of Cleansers

Expert acne specialists discuss the types of cleansers available on the market.

The Mainstream Patient: August 29

This week's edition of the Mainstream Patient features stories about tattoo aftercare, expert-reviewed wrinkle creams, trending Latinx beauty brands, and more.

Positive Results from Phase 2b Study of TMB-001 for Congenital Ichthyosis

Timber Pharmaceuticals’ CONTROL study evaluated the safety and efficacy of the topical isotretinoin.

New Research Finds Shared Decision-Making Beneficial in Care of Patients With Eczema

New research by the National Eczema Association has revealed the importance of patient input into treatment decisions.

Looking Beyond High Inflation

Positioning your portfolio for price stability and growth.

Case 1: 2-Year-Old Male With Atopic Dermatitis

Dr Joshua Zeichner reviews the case of a 2-year-old patient with atopic dermatitis.

Case 1 Continued: Clinical Impressions

Expert pediatric dermatologists Drs Elizabeth Swanson, Joshua Zeichner, and Raj Chovatiya share impressions from patient case No. 1.

Case 1 Continued: Treatments Beyond Topical Agents and the Use of Dupixent

Joshua Zeichner, MD; Brittany Craiglow, MD; Elizabeth Swanson, MD; Vikash Oza, MD; and Raj Chovatiya, MD, PhD, discuss treatments beyond topical agents and the use of dupilumab in pediatric patients with atopic dermatitis.

Case 2: 7-Year-Old Female With Atopic Dermatitis

Dr Joshua Zeichner reviews the case of a 7-year-old female patient with atopic dermatitis.

Pointers with Dr Portela: How to Treat Tinea Versicolor

In this week’s Pointers with Dr Portela, the 208SkinDoc discusses how to treat tinea versicolor.

New Data from AbbVie Will Be Presented at EADV 2022 Congress

Abstracts will include updates on treatment for psoriatic arthritis, psoriasis, atopic dermatitis, and more.

What's Trending in Skin Care: August 2022

Each month, Dermatology Times® features a roundup of products trending in skin care. Find out what products are trending for the month of August.

Case 2 Continued: Addressing Injectable Medications in Children

Joshua Zeichner, MD; Brittany Craiglow, MD; Elizabeth Swanson, MD; and Vikash Oza, MD, address techniques for injectables when treating pediatric patients with atopic dermatitis.

Case 2 Continued: Impressions and Recommendations

Vikash Oza, MD, provides clinical insight for Case 2, a 7-year-old female patient with atopic dermatitis.

Case 2 Continued: Barriers to Treatment Adherence

Brittany Craiglow, MD, and Joshua Zeichner, MD, discuss treatment adherence in pediatric patients with atopic dermatitis.

Case 2 Continued: Importance of Combination Therapy and Shared Decision Making

Expert pediatric dermatologists discuss the importance of combination therapy and shared decision-making when treating pediatric patients with atopic dermatitis.

Enrollment Milestone Achieved in Phase 3 Clinical Trials for DFD-29 Treatment of PPR

Topline data expected in the first half of 2023.

Imsidolimab Development for HS Discontinued

AnaptysBio will refocus R&D efforts on its immune cell modulator pipeline.

FDA Grants Extended Clearance of Avéli for the Reduction of Cellulite

Revelle Aesthetics’ cellulite reduction device helps address frustrating aesthetic concerns.

FDA Approves Spesolimab-Sbzo Injection for GPP Flares

Boehringer Ingelheim’s first treatment option for adults will help manage burdensome flares.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.